Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.
Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.
University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.
"In a long-awaited study that helped prompt a contentious debate over the wisdom of conducting research that has the potential to help as well as harm, scientists reported Wednesday that they had engineered a mutant strain of [H5N1] bird flu that can spread easily between ferrets -- a laboratory animal that responds to flu viruses much as people do," the Los Angeles Times (Brown, 5/3).
Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.
All Care Inala Medical Centre doctor Michael Ho said flu shots were becoming more popular each year. “Flu seasons tends to begin in late March early April to June,” he said. “More and more people are opting to get vaccinations because they are promoted well within the community.” He added, “It is particularly important for elderly people to be immunized because their immune system is already not at its best…This is also the case for people who have chronic medical conditions like diabetes, severe asthma, or heart disease. With their current condition, if they catch the flu they can end up with a worse outcome.”
Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.
PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported the launch of the PURE Complete Cleaning, Sanitizing and Disinfecting System.
NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.
Researchers at the University of British Columbia have identified a number of tiny but powerful "genetic regulators" that are hijacked by avian and swine flu viruses during human infection.
The H1N1 flu pandemic in 2009 underscored weaknesses in methods widely used to diagnose the flu, from frequent false negatives to long wait times for results. Now Boston University researchers have developed a prototype of a rapid, low-cost, accurate, point-of-care device that promises to provide clinicians with an effective tool to quickly diagnose both seasonal and pandemic strains of influenza, and thus limit the spread of infection.
Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon universal vaccine related to H1N1 influenza.
A genetic finding could help explain why influenza becomes a life-threating disease to some people while it has only mild effects in others. New research led by the Wellcome Trust Sanger Institute has identified for the first time a human gene that influences how we respond to influenza infection.
NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
While some scientists report engineering a super virulent strain of the H5N1 influenza virus, which could potentially wipe out a significant percentage of the human population, another group of researchers from the United Kingdom now reports a discovery that may one day help mitigate the deadly effects of all flu strains.
MedImmune today announced that the U.S. Food and Drug Administration (FDA) has approved FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of influenza.
A new study conducted by researchers from McGill University, the Research Institute of the McGill University Health Centre (RI MUHC), and Sainte-Justine University Hospital Research Centre, Montreal, has put the accuracy of rapid influenza diagnostic tests (RIDTs) under the microscope.
Dr. Joseph Bresee, chief of the epidemiology prevention branch at the influenza division at the Centers for Disease Control and Prevention (CDC), said for the third consecutive week this season the percent of respiratory specimen testing positive for flu surpassed 10 percent, which is generally a marker to indicate the flu season has begun. “This is the latest start to a flu season in the past 29 years,” said Dr. Bresee.
The H5N1 influenza virus commonly called “bird flu” or “avian flu” could be more prevalent and less deadly than health officials had thought, according to a new study published online (Feb. 23) by the journal Science.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.